663 related articles for article (PubMed ID: 30343824)
1. Cardiovascular disease models: A game changing paradigm in drug discovery and screening.
Savoji H; Mohammadi MH; Rafatian N; Toroghi MK; Wang EY; Zhao Y; Korolj A; Ahadian S; Radisic M
Biomaterials; 2019 Apr; 198():3-26. PubMed ID: 30343824
[TBL] [Abstract][Full Text] [Related]
2. Induced pluripotent stem cells in cardiovascular drug discovery.
Mercola M; Colas A; Willems E
Circ Res; 2013 Feb; 112(3):534-48. PubMed ID: 23371902
[TBL] [Abstract][Full Text] [Related]
3. Human pluripotent stem cell-based cardiovascular disease modeling and drug discovery.
Liu G; Liu Z; Cao N
Pflugers Arch; 2021 Jul; 473(7):1087-1097. PubMed ID: 33686477
[TBL] [Abstract][Full Text] [Related]
4. Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation.
Portillo-Lara R; Spencer AR; Walker BW; Shirzaei Sani E; Annabi N
Biomaterials; 2019 Apr; 198():78-94. PubMed ID: 30201502
[TBL] [Abstract][Full Text] [Related]
5. Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery.
Qian L; Tcw J
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33530458
[TBL] [Abstract][Full Text] [Related]
6. Human-induced pluripotent stem cells in cardiovascular research: current approaches in cardiac differentiation, maturation strategies, and scalable production.
Thomas D; Cunningham NJ; Shenoy S; Wu JC
Cardiovasc Res; 2022 Jan; 118(1):20-36. PubMed ID: 33757124
[TBL] [Abstract][Full Text] [Related]
7. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
8. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
9. A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.
Mordwinkin NM; Burridge PW; Wu JC
J Cardiovasc Transl Res; 2013 Feb; 6(1):22-30. PubMed ID: 23229562
[TBL] [Abstract][Full Text] [Related]
10. Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences.
Abi-Gerges N; Miller PE; Ghetti A
Curr Pharm Biotechnol; 2020; 21(9):787-806. PubMed ID: 31820682
[TBL] [Abstract][Full Text] [Related]
11. Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.
Tzatzalos E; Abilez OJ; Shukla P; Wu JC
Adv Drug Deliv Rev; 2016 Jan; 96():234-244. PubMed ID: 26428619
[TBL] [Abstract][Full Text] [Related]
12. The Application of Induced Pluripotent Stem Cells in Cardiac Disease Modeling and Drug Testing.
Ye L; Ni X; Zhao ZA; Lei W; Hu S
J Cardiovasc Transl Res; 2018 Oct; 11(5):366-374. PubMed ID: 29845439
[TBL] [Abstract][Full Text] [Related]
13. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing.
Shaheen N; Shiti A; Gepstein L
Clin Pharmacol Ther; 2017 Aug; 102(2):203-208. PubMed ID: 28718902
[TBL] [Abstract][Full Text] [Related]
14. Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.
Lam CK; Wu JC
Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):1019-1031. PubMed ID: 33472401
[TBL] [Abstract][Full Text] [Related]
15. High throughput physiological screening of iPSC-derived cardiomyocytes for drug development.
Del Álamo JC; Lemons D; Serrano R; Savchenko A; Cerignoli F; Bodmer R; Mercola M
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1717-27. PubMed ID: 26952934
[TBL] [Abstract][Full Text] [Related]
16. Concise review: drug discovery in the age of the induced pluripotent stem cell.
Ko HC; Gelb BD
Stem Cells Transl Med; 2014 Apr; 3(4):500-9. PubMed ID: 24493856
[TBL] [Abstract][Full Text] [Related]
17. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells.
Csöbönyeiová M; Polák Š; Danišovič L
Can J Physiol Pharmacol; 2016 Jul; 94(7):687-94. PubMed ID: 27128322
[TBL] [Abstract][Full Text] [Related]
18. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.
Sallam K; Li Y; Sager PT; Houser SR; Wu JC
Circ Res; 2015 Jun; 116(12):1989-2004. PubMed ID: 26044252
[TBL] [Abstract][Full Text] [Related]
19. Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms.
Pang L; Sager P; Yang X; Shi H; Sannajust F; Brock M; Wu JC; Abi-Gerges N; Lyn-Cook B; Berridge BR; Stockbridge N
Circ Res; 2019 Oct; 125(9):855-867. PubMed ID: 31600125
[TBL] [Abstract][Full Text] [Related]
20. The updated view on induced pluripotent stem cells for cardiovascular precision medicine.
Wang Y; Lei W; Yang J; Ni X; Ye L; Shen Z; Hu S
Pflugers Arch; 2021 Jul; 473(7):1137-1149. PubMed ID: 33595719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
